{"id":756124,"date":"2023-05-08T16:38:42","date_gmt":"2023-05-08T20:38:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/"},"modified":"2023-05-08T16:38:42","modified_gmt":"2023-05-08T20:38:42","slug":"adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/","title":{"rendered":"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, May  08, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=o1nrcnQCCLybkhw2YpiFifLZEctCjKPpCs63aNRT_d3Fyldy_HDcSdEbKst0d5gxt9WP8TNtR5OJ95HpkmfbSi438dKF6KVAPcwFu5G1TpjvxAyjEWY7hI5_econGjB5\" rel=\"nofollow noopener\" target=\"_blank\">Adamis Pharmaceuticals Corporation<\/a> (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company\u2019s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as well as the proposals to be considered and acted upon at the meeting. The company\u2019s first quarter 2023 financial results news release is expected to be available after 1:00 p.m. Pacific Time on May 15, 2023, and on its <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vvd5c3RHx-FSRD2822o_RSYkp2qI-eNOmGtqRdjlG207rcugZ0XQGav84EEEpBjC-KUiOrJlTuCVZSmULU4thWCaRG5oKiuCMpVvQukFEZI=\" rel=\"nofollow noopener\" target=\"_blank\">website<\/a>.<\/p>\n<p>Event: Adamis Pharmaceuticals First Quarter 2023 Financial Results Conference Call<br \/>Date: Monday, May 15, 2023<br \/>Time: 2 p.m. PT (5 p.m. ET)<br \/>U.S. Dial-in (Toll Free): 1-877-423-9813<br \/>Toll\/International Dial-in: 1-201-689-8573<\/p>\n<p>David J. Marguglio, President and CEO of Adamis, will host the call along with other members of the management team. The call is open to the public and will provide an update on recent developments, events that have taken place during the year, and certain goals for future periods, and may also include an update concerning the results of the company\u2019s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as well as the proposals to be considered and acted upon at the meeting. Forward-looking statements concerning expectations regarding future company performance may be made during the conference call.<\/p>\n<p>A live audio webcast of the conference call will also be available via this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6BAqGCM9G7XAXLAwz3OubQ1aCmSeVfIVRgydWKr-SLFG2F0jKO2DRNLnMGvABKYNN-yKmgYHJzRTYOdZOVP7H69_AvRqFRaCPKWXjYxhnuhEvuw5WgI5AZFnkZDeLrKe\" rel=\"nofollow noopener\" target=\"_blank\">link<\/a>, with a replay available shortly after the live event.<\/p>\n<p>\n        <strong>About Adamis Pharmaceuticals<\/strong>\n      <\/p>\n<p>Adamis Pharmaceuticals Corporation\u00a0is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease. Company products approved by the FDA include <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9Is0uED7GBDdF7ysUxkB6ylw7gLoaM5BqLwhebamElPJ2vE8gnejCmZK09yMYxts\" rel=\"nofollow noopener\" target=\"_blank\">ZIMHI<\/a><sup>\u00ae<\/sup>\u00a0(naloxone) Injection for the treatment of opioid overdose and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XNGJNCzxVtff3VROPCi6bTRXJT96yYGyVvoY-L08QlQw8HwaFMAZpw4VnKjeg0uCIUTIN7xcoG-Gl09jAXeTXg==\" rel=\"nofollow noopener\" target=\"_blank\">SYMJEPI<\/a><sup>\u00ae<\/sup>\u00a0(epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. For additional information about\u00a0Adamis Pharmaceuticals, please visit our\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vvd5c3RHx-FSRD2822o_RSMpsIbmSpXW4C2eHsfb_5dGWNA2TkiLUa7Ag9IyWVSgQntafCftDHH-W1PLAEGAbb3j7OZZFpfx2YZL9-yI2gM=\" rel=\"nofollow noopener\" target=\"_blank\">website<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OaHVPuAgheoYbfn7Ucppddm2S-nVSQUR_1lliGuIfsTUg7Utd7MW7XRE22FA0jLknYx7dm5-Dmx4OJZDLPDAFQ==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FKRCS6Zd45sj6MgSEyzsun_nnFnB8tYbnJOFo8MqOolfCQjiiFsIqKXfSdA56GLxyIJY2NI8SekTgfPY4GqR8Bt8wS3QX7o2fq7W7TJ-_zpyxPrBorZdU1BHgyezZb-teo2N6BYKZCn_-pUl4C5qTg==\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>. \u00a0\u00a0<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>Adamis Investor Relations <br \/>Robert Uhl<br \/>Managing Director<br \/>ICR Westwicke <br \/>619.228.5886<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YoHB33Z9bHB_PScErwOoGz8U6jHVBHxW71JxvQnM7c9UTfoZ1mOHXfBBB6KMNFUMk_2NAdp7XYrar0KqjdszKoc6yoAqpS9WaEHVeTKdlFc=\" rel=\"nofollow noopener\" target=\"_blank\">robert.uhl@westwicke.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODFiNWYxNGItNjI0Ny00OTM0LTg3ZDItZjMzNjY1ZDg2YWNhLTEwMjg5MzI=\/tiny\/Adamis-Pharmaceuticals-Corpora.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) &#8212; Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company\u2019s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as well as the proposals to be considered and acted upon at the meeting. The company\u2019s first &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-756124","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) &#8212; Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company\u2019s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as well as the proposals to be considered and acted upon at the meeting. The company\u2019s first &hellip; Continue reading &quot;Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-08T20:38:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update\",\"datePublished\":\"2023-05-08T20:38:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/\"},\"wordCount\":401,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/\",\"name\":\"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk=\",\"datePublished\":\"2023-05-08T20:38:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update - Market Newsdesk","og_description":"SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) &#8212; Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company\u2019s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as well as the proposals to be considered and acted upon at the meeting. The company\u2019s first &hellip; Continue reading \"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-08T20:38:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update","datePublished":"2023-05-08T20:38:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/"},"wordCount":401,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/","name":"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk=","datePublished":"2023-05-08T20:38:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDIyOSM1NTgxMzIxIzIwMTczNTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-first-quarter-2023-financial-results-conference-call-and-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=756124"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756124\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=756124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=756124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=756124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}